会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • &bgr;-L-2′-deoxy-nucleosides for the treatment of hepatitis B
    • β-L-2'-脱氧核苷用于治疗乙型肝炎
    • US06566344B1
    • 2003-05-20
    • US10022148
    • 2001-12-14
    • Gilles GosselinJean-Louis ImbachMartin L. Bryant
    • Gilles GosselinJean-Louis ImbachMartin L. Bryant
    • A61K3170
    • C07H19/16A61K31/70A61K31/7068A61K31/7072A61K31/7076A61K31/708C07H19/06A61K2300/00
    • This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-&bgr;-L-erythro-pentoftiranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.
    • 本发明涉及一种用于治疗感染乙型肝炎的宿主的方法,其包括施用有效量的抗HBV生物活性2'-脱氧-β-L-赤 - 戊呋喃核苷或其药学上可接受的盐或前药,其中 2'-脱氧-β-L-赤式 - 戊烯基核苷具有下式:其中R选自H,直链,支链或环状烷基,CO-烷基,CO-芳基,CO-烷氧基烷基,CO-芳氧基烷基 烷基磺酰基,芳基磺酰基,芳烷基磺酰基,氨基酸残基,单,二或三磷酸酯,或磷酸酯衍生物; 并且BASE是嘌呤或嘧啶碱基,其可任选被取代。 2'-脱氧-β-L-赤 - 戊呋喃核苷或其药学上可接受的盐或前药可以单独或与其它2'-脱氧-β-L-赤 - 戊呋喃核苷组合或与另一种抗 - 乙型肝炎药。
    • 2. 发明授权
    • β-L-2′-deoxy-nucleosides for the treatment of hepatitis B
    • β-L-2'-脱氧核苷用于治疗乙型肝炎
    • US06946450B2
    • 2005-09-20
    • US10437802
    • 2003-05-13
    • Gilles GosselinJean-Louis ImbachMartin L. Bryant
    • Gilles GosselinJean-Louis ImbachMartin L. Bryant
    • A61K31/7068A61K31/7072A61K31/7076A61K31/708C07H19/06C07H19/16A61K31/70C07H19/073
    • C07H19/16A61K31/70A61K31/7068A61K31/7072A61K31/7076A61K31/708C07H19/06A61K2300/00
    • This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-β-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.
    • 本发明涉及一种用于治疗感染乙型肝炎的宿主的方法,其包括施用有效量的抗HBV生物活性2'-脱氧-β-L-赤 - 戊呋喃核苷或其药学上可接受的盐或前药,其中 2'-脱氧-β-L-赤 - 戊呋喃核苷具有下式:其中R选自H,直链,支链或环状烷基,CO-烷基,CO-芳基,CO-烷氧基烷基,CO-芳氧基烷基 烷基磺酰基,芳基磺酰基,芳烷基磺酰基,氨基酸残基,单,二或三磷酸酯,或磷酸酯衍生物; 并且BASE是嘌呤或嘧啶碱基,其可任选被取代。 2'-脱氧-β-L-赤 - 戊呋喃核苷或其药学上可接受的盐或前药可以单独或与其它2'-脱氧-β-L-赤 - 戊呋喃核苷组合或与另一种抗 - 乙型肝炎药。
    • 4. 发明授权
    • β-L-2′-deoxy-nucleosides for the treatment of hepatitis B
    • &bgr; -L-2'-脱氧核苷用于治疗乙型肝炎
    • US07795238B2
    • 2010-09-14
    • US11929798
    • 2007-10-30
    • Gilles GosselinJean-Louis ImbachMartin L. Bryant
    • Gilles GosselinJean-Louis ImbachMartin L. Bryant
    • A61K31/70
    • C07H19/16A61K31/70A61K31/7068A61K31/7072A61K31/7076A61K31/708C07H19/06A61K2300/00
    • This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-β-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.
    • 本发明涉及一种用于治疗感染乙型肝炎的宿主的方法,其包括给予有效量的抗HBV生物活性2'-脱氧-α-胆红素 - 戊呋喃核苷或其药学上可接受的盐或前药,其中 2-脱氧-β-赤 - 戊呋喃核苷具有下式:其中R选自H,直链,支链或环状烷基,CO-烷基,CO-芳基,CO-烷氧基烷基,CO 芳基磺酰基,氨基酸残基,单,二或三磷酸酯,或磷酸酯衍生物; 并且BASE是嘌呤或嘧啶碱基,其可任选被取代。 2'-脱氧-β-赤 - 戊呋喃核苷或其药学上可接受的盐或前药可以单独给药或与另外2'-脱氧-α-赤 - 戊呋喃核苷一起施用或与另一种 抗乙型肝炎药。
    • 7. 发明申请
    • Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B
    • 用于治疗乙型肝炎的β-L-2'-Deoxy-Nucleosides
    • US20080188440A1
    • 2008-08-07
    • US11929798
    • 2007-10-30
    • Gilles GosselinJean-Louis ImbachMartin L. Bryant
    • Gilles GosselinJean-Louis ImbachMartin L. Bryant
    • A61K31/7072A61P31/20
    • C07H19/16A61K31/70A61K31/7068A61K31/7072A61K31/7076A61K31/708C07H19/06A61K2300/00
    • This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-β-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.
    • 本发明涉及一种用于治疗感染乙型肝炎的宿主的方法,其包括施用有效量的抗HBV生物活性2'-脱氧-β-L-赤 - 戊呋喃核苷或其药学上可接受的盐或前药,其中 2'-脱氧-β-L-赤 - 戊呋喃核苷具有下式:其中R选自H,直链,支链或环状烷基,CO-烷基,CO-芳基,CO-烷氧基烷基,CO-芳氧基烷基 烷基磺酰基,芳基磺酰基,芳烷基磺酰基,氨基酸残基,单,二或三磷酸酯,或磷酸酯衍生物; 并且BASE是嘌呤或嘧啶碱基,其可任选被取代。 2'-脱氧-β-L-赤 - 戊呋喃核苷或其药学上可接受的盐或前药可以单独或与其它2'-脱氧-β-L-赤 - 戊呋喃核苷组合或与另一种抗 - 乙型肝炎药。